1、Regulations and Markets-Generics-Innovation-Contract ServicesNutraceuticals-Medical Devices-Digital HealthINDIA LIFE SCIENCES 2023GBR SERIESINDIALIFE SCIENCES2023GBR SERIESDear Reader,Welcome to our India Life Sciences 2023 special report.Indias pharmaceutical industry,ranked third worldwide in term

2、s of volume,is the largest supplier of generic drugs and is well-regarded for the role it plays in making high-quality medicines and vaccines affordable to the global population.Fueled by domestic and foreign demand,the sector continues to grow;currently a US$50 billion industry,optimistic forecasts

3、 project the Indian pharmaceutical industry could reach US$150 billion within a decade.Amid a competitive landscape,Indian companies operating in the life sci-ences have carved out niches for themselves in various ways whether it be researching novel drug delivery systems,introducing new molecules a

4、nd materials to the market,or securing funding for work in the countrys nascent biotech sector,innovation abounds.At the same time,certain sub-sectors of the life sciences are witnessing a surge in interest in the wake of Covid-19,propelled by heightened consumer demand and a flourish of entrepreneu

5、rial activity to keep pace.This report will investigate the activi-ties surrounding such advancements in the nutraceuticals,digital health,and medical devices spaces.Of course,the magnitude of success does not rest squarely on the shoul-ders of only pharmaceutical and biopharmaceutical companies con

6、tract service providers are crucial to the health of the life sciences ecosystem.Responding to the heightened complexity of the field,CROs and CDMOs are stepping up to create a more robust environment.For 2023,geopoliti-cal trends seem to be working in their favor;against the backdrop of Sino-Wester